SE514606C2 - Läkemedel innehållande GnRH-analoger för behandling av schizofreni - Google Patents

Läkemedel innehållande GnRH-analoger för behandling av schizofreni

Info

Publication number: SE514606C2
Authority: SE; Sweden
Prior art keywords: treatment; schizophrenia; gnrh; androgenic; use according
Prior art date: 1998-08-26

Application number

SE9802836A

Other languages

English (en)

Swedish (sv)

Other versions

SE9802836L (sv

SE9802836D0 (sv

Inventor

Tomas Eriksson

Original Assignee

Laekartjaenster I Vaestsverige

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-26

Filing date

1998-08-26

Publication date

2001-03-19

1998-08-26 Application filed by Laekartjaenster I Vaestsverige filed Critical Laekartjaenster I Vaestsverige

1998-08-26 Priority to SE9802836A priority Critical patent/SE514606C2/sv

1998-08-26 Publication of SE9802836D0 publication Critical patent/SE9802836D0/xx

1999-08-25 Priority to AU58904/99A priority patent/AU5890499A/en

1999-08-25 Priority to US09/786,149 priority patent/US6468973B1/en

1999-08-25 Priority to EP99946505A priority patent/EP1115415B1/de

1999-08-25 Priority to DE69915849T priority patent/DE69915849D1/de

1999-08-25 Priority to AT99946505T priority patent/ATE262343T1/de

1999-08-25 Priority to PCT/SE1999/001441 priority patent/WO2000012115A1/en

2000-02-27 Publication of SE9802836L publication Critical patent/SE9802836L/xx

2001-03-19 Publication of SE514606C2 publication Critical patent/SE514606C2/sv

Links

238000011282 treatment Methods 0.000 title claims abstract description 43
201000000980 schizophrenia Diseases 0.000 title claims abstract description 20
239000003814 drug Substances 0.000 title claims abstract description 19
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 title claims 5
229940079593 drug Drugs 0.000 title abstract description 18
239000000126 substance Substances 0.000 claims abstract description 11
239000000203 mixture Substances 0.000 claims abstract description 6
210000004556 brain Anatomy 0.000 claims description 13
108010050144 Triptorelin Pamoate Proteins 0.000 claims description 12
VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 claims description 11
229960004824 triptorelin Drugs 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 8
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 7
238000002347 injection Methods 0.000 claims description 6
239000007924 injection Substances 0.000 claims description 6
229960002074 flutamide Drugs 0.000 claims description 4
108010037003 Buserelin Proteins 0.000 claims description 3
108010069236 Goserelin Proteins 0.000 claims description 3
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 3
102000001307 androgen receptors Human genes 0.000 claims description 3
108010080146 androgen receptors Proteins 0.000 claims description 3
230000000903 blocking effect Effects 0.000 claims description 3
CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
108010000817 Leuprolide Proteins 0.000 claims description 2
229960002719 buserelin Drugs 0.000 claims description 2
229960002913 goserelin Drugs 0.000 claims description 2
229960004338 leuprorelin Drugs 0.000 claims description 2
239000007922 nasal spray Substances 0.000 claims description 2
229940097496 nasal spray Drugs 0.000 claims description 2
229950005627 embonate Drugs 0.000 claims 1
238000010255 intramuscular injection Methods 0.000 claims 1
239000007927 intramuscular injection Substances 0.000 claims 1
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims 1
238000010254 subcutaneous injection Methods 0.000 claims 1
239000007929 subcutaneous injection Substances 0.000 claims 1
208000024891 symptom Diseases 0.000 abstract description 17
230000001548 androgenic effect Effects 0.000 description 30
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 25
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 22
229940088597 hormone Drugs 0.000 description 22
239000005556 hormone Substances 0.000 description 22
239000008280 blood Substances 0.000 description 18
210000004369 blood Anatomy 0.000 description 18
230000000694 effects Effects 0.000 description 17
230000015572 biosynthetic process Effects 0.000 description 12
238000000034 method Methods 0.000 description 11
229960003604 testosterone Drugs 0.000 description 11
201000010099 disease Diseases 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 8
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 8
229940035638 gonadotropin-releasing hormone Drugs 0.000 description 8
102000005962 receptors Human genes 0.000 description 8
108020003175 receptors Proteins 0.000 description 8
102000006771 Gonadotropins Human genes 0.000 description 7
108010086677 Gonadotropins Proteins 0.000 description 7
239000002622 gonadotropin Substances 0.000 description 7
239000003098 androgen Substances 0.000 description 6
229940094892 gonadotropins Drugs 0.000 description 6
230000002280 anti-androgenic effect Effects 0.000 description 5
230000035945 sensitivity Effects 0.000 description 5
230000009467 reduction Effects 0.000 description 4
230000001568 sexual effect Effects 0.000 description 4
206010012239 Delusion Diseases 0.000 description 3
208000004547 Hallucinations Diseases 0.000 description 3
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 3
206010060862 Prostate cancer Diseases 0.000 description 3
208000000236 Prostatic Neoplasms Diseases 0.000 description 3
230000001447 compensatory effect Effects 0.000 description 3
231100000868 delusion Toxicity 0.000 description 3
210000004907 gland Anatomy 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
208000012239 Developmental disease Diseases 0.000 description 2
208000016619 Histrionic personality disease Diseases 0.000 description 2
208000028017 Psychotic disease Diseases 0.000 description 2
230000001944 accentuation Effects 0.000 description 2
208000030963 borderline personality disease Diseases 0.000 description 2
UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 2
230000002354 daily effect Effects 0.000 description 2
230000002222 downregulating effect Effects 0.000 description 2
208000003481 exhibitionism Diseases 0.000 description 2
230000003631 expected effect Effects 0.000 description 2
208000013403 hyperactivity Diseases 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
230000028327 secretion Effects 0.000 description 2
ZBVJFYPGLGEMIN-OYLNGHKZSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-( Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1.C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 ZBVJFYPGLGEMIN-OYLNGHKZSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
206010020112 Hirsutism Diseases 0.000 description 1
206010066364 Hypersexuality Diseases 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
206010033888 Paraphilia Diseases 0.000 description 1
208000032769 Pedophilia Diseases 0.000 description 1
206010039367 Sadism Diseases 0.000 description 1
230000009471 action Effects 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
239000000051 antiandrogen Substances 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
229960000978 cyproterone acetate Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000009123 feedback regulation Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000003163 gonadal steroid hormone Substances 0.000 description 1
208000024963 hair loss Diseases 0.000 description 1
230000003676 hair loss Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000002969 morbid Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
238000011458 pharmacological treatment Methods 0.000 description 1
230000007180 physiological regulation Effects 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
230000008569 process Effects 0.000 description 1
239000003488 releasing hormone Substances 0.000 description 1
230000009291 secondary effect Effects 0.000 description 1
230000009329 sexual behaviour Effects 0.000 description 1
230000036299 sexual function Effects 0.000 description 1
230000035936 sexual power Effects 0.000 description 1
201000005841 sexual sadism Diseases 0.000 description 1
208000027596 sexual sadism disease Diseases 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000003319 supportive effect Effects 0.000 description 1
239000012622 synthetic inhibitor Substances 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
229940033942 zoladex Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Soundproofing, Sound Blocking, And Sound Damping (AREA)
Networks Using Active Elements (AREA)

SE9802836A 1998-08-26 1998-08-26 Läkemedel innehållande GnRH-analoger för behandling av schizofreni SE514606C2 (sv)

Priority Applications (7)

Application Number	Priority Date	Filing Date	Title
SE9802836A SE514606C2 (sv)	1998-08-26	1998-08-26	Läkemedel innehållande GnRH-analoger för behandling av schizofreni
AU58904/99A AU5890499A (en)	1998-08-26	1999-08-25	Use of composition in the treatment of schizophrenia
US09/786,149 US6468973B1 (en)	1998-08-26	1999-08-25	Method in the treatment of schizophrenia
EP99946505A EP1115415B1 (de)	1998-08-26	1999-08-25	Verwendung von gnrh analogen zur behandlung von schizophrenie
DE69915849T DE69915849D1 (de)	1998-08-26	1999-08-25	Verwendung von gnrh analogen zur behandlung von schizophrenie
AT99946505T ATE262343T1 (de)	1998-08-26	1999-08-25	Verwendung von gnrh analogen zur behandlung von schizophrenie
PCT/SE1999/001441 WO2000012115A1 (en)	1998-08-26	1999-08-25	Use of composition in the treatment of schizophrenia

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE9802836A SE514606C2 (sv)	1998-08-26	1998-08-26	Läkemedel innehållande GnRH-analoger för behandling av schizofreni

Publications (3)

Publication Number	Publication Date
SE9802836D0 SE9802836D0 (sv)	1998-08-26
SE9802836L SE9802836L (sv)	2000-02-27
SE514606C2 true SE514606C2 (sv)	2001-03-19

Family

ID=20412345

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE9802836A SE514606C2 (sv)	1998-08-26	1998-08-26	Läkemedel innehållande GnRH-analoger för behandling av schizofreni

Country Status (7)

Country	Link
US (1)	US6468973B1 (de)
EP (1)	EP1115415B1 (de)
AT (1)	ATE262343T1 (de)
AU (1)	AU5890499A (de)
DE (1)	DE69915849D1 (de)
SE (1)	SE514606C2 (de)
WO (1)	WO2000012115A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9802438L (sv) *	1998-07-07	1999-07-19	Laekartjaenster I Vaestsverige	Användning av komposition omfattande minst ett ämne inom gruppen GnRH-analoger för framställning av ett läkemedel för behandling av tvångstanke-tvångshandlingssjukdom
IL147138A0 (en)	2001-12-17	2002-08-14	Yeda Res & Dev	Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4474813A (en) *	1980-10-24	1984-10-02	Schering Corporation	Pharmaceutical preparations comprising flutamide
DE3726324A1 (de) *	1987-08-07	1989-02-16	Hoechst Ag	Cyclopeptide als resorptionsfoerderer bei applikation auf die schleimhaeute
FR2661180B1 (fr) *	1990-04-23	1995-04-28	Inst Nat Sante Rech Med	(hydroxyproline 9) lhrh, son procede d'obtention et application comme medicament.
RU2091390C1 (ru) *	1995-02-28	1997-09-27	Научно-исследовательский институт фармакологии РАН	Замещенные пролилтирозины, обладающие психотропной активностью

1998
- 1998-08-26 SE SE9802836A patent/SE514606C2/sv not_active IP Right Cessation
1999
- 1999-08-25 AT AT99946505T patent/ATE262343T1/de not_active IP Right Cessation
- 1999-08-25 AU AU58904/99A patent/AU5890499A/en not_active Abandoned
- 1999-08-25 WO PCT/SE1999/001441 patent/WO2000012115A1/en not_active Ceased
- 1999-08-25 DE DE69915849T patent/DE69915849D1/de not_active Expired - Lifetime
- 1999-08-25 US US09/786,149 patent/US6468973B1/en not_active Expired - Fee Related
- 1999-08-25 EP EP99946505A patent/EP1115415B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US6468973B1 (en)	2002-10-22
EP1115415A1 (de)	2001-07-18
ATE262343T1 (de)	2004-04-15
DE69915849D1 (de)	2004-04-29
SE9802836L (sv)	2000-02-27
WO2000012115A1 (en)	2000-03-09
EP1115415B1 (de)	2004-03-24
SE9802836D0 (sv)	1998-08-26
AU5890499A (en)	2000-03-21

Legal Events

Date	Code	Title	Description
2005-03-29	NUG	Patent has lapsed

Publication	Publication Date	Title
Ray et al.	2017	Stress, anxiety, and immunomodulation: a pharmacological analysis
Follesa et al.	2007	Vagus nerve stimulation increases norepinephrine concentration and the gene expression of BDNF and bFGF in the rat brain
Gillberg	1995	Endogenous opioids and opiate antagonists in autism: brief review of empirical findings and implications for clinicians
Briken, Evangelia Nika, Wolfgang Berner	2001	Treatment of paraphilia with luteinizing hormone-releasing hormone agonists
Cuevas-Ramos et al.	2014	Treatment of Cushing’s disease: a mechanistic update
Zhu et al.	2019	Electro-acupuncture affects the activity of the hypothalamic-pituitary-ovary axis in female rats
Warner et al.	2016	Breaking BAT: can browning create a better white?
PT1011648E (pt)	2002-03-28	Combinacao do inibidor de tirosina cinase e castracao quimica para tratar o cancro da prostata
US20070259939A1 (en)	2007-11-08	Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
AU747807B2 (en)	2002-05-23	Testosterone inhibitors and use for the protection of neurons
Yang et al.	2017	Altered neuroendocrine immune responses, a two-sword weapon against traumatic inflammation
Telegdy et al.	2012	Involvement of neurotransmitters in the action of growth hormone-releasing hormone antagonist on passive avoidance learning
Telegdy et al.	2012	Neurotransmitter-mediated action of an antagonist of growth hormone-releasing hormone on anxiolysis in mice
SE514606C2 (sv)	2001-03-19	Läkemedel innehållande GnRH-analoger för behandling av schizofreni
EP1094830B1 (de)	2005-09-21	Verwendung einer zusammensetzung enthaltend zumindest ein gnrh-analoges zur behandlung von zwangsneurotischen erkrankungen
Gómora-Arrati et al.	2019	Copulation-induced antinociception in female rats is blocked by atosiban, an oxytocin receptor antagonist
JP5395437B2 (ja)	2014-01-22	ステロイド化合物の治療使用
EP0565674B1 (de)	1999-01-07	Verfahren zur verbesserung des gedächtnisses und zur steigerung der lebensqualitet
Kapur et al.	2019	The multifarious oxytocin: a review
Foy et al.	2006	Neurobiological foundations of stress
Tryba	2000	Alpha2-adrenoceptor agonists in intensive care medicine: Prevention and treatment of withdrawal
JP2009515939A5 (de)	2012-11-08
SIA	2018	Role of hormonal manipulation in prostate cancer management
Tawfeeq et al.	2016	Effect of pregabalin on ovary tissue of albino female rats
Sharma	2015	INSULIN COMA TREATMENT: FACTS & CONTROVERSIES